Description

BeOne Medicines’ $1.1 Billion BRUKINSA Engine: Can Oncology Momentum Last?

BeOne Medicines reported its first-quarter 2026 results with significant momentum across its commercial and clinical operations, reflected in robust financial performance and strategic pipeline advancement. Product revenue reached $1.5 billion, up 34% year-over-year, driven primarily by strong sales of BRUKINSA, the company’s BTK inhibitor, which generated $1.1 billion in global revenues, marking a 38% increase. The US market remained the largest contributor, with $761 million in BRUKINSA sales, supported by volume growth and stable pricing, albeit with typical seasonality effects due to one fewer shipping week in the quarter. Other products such as TEVIMBRA showed a 20% revenue increase, maintaining leadership in China, and the next-generation BCL-2 inhibitor sonro demonstrated early market acceptance following approval in China.